Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
2012
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
2014
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
2010
Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
2009
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
1994
Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer
2009
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Role of adjuvant chemotherapy in male breast cancer
1989
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
A view on drug resistance in cancer
2019 StandoutNature
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
2008
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual
2003
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
2003
Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
1992
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Population-based screening for cancer: hope and hype
2016
A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast Cancer
1992
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
2001 Standout
A Comparison of Observational Studies and Randomized, Controlled Trials
2000 Standout
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
1997
Users' Guides to the Medical Literature
2000 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Male breast cancer
2006 Standout
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer
2000
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Apoptosis
2002 Standout
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
2005 Standout
Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma
2001
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
1991
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Impact of axillary lymph node dissection on the therapy of breast cancer patients.
1993
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Annual hazard rates of recurrence for breast cancer after primary therapy.
1996
Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999
2002
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
2015
Breast cancer adjuvant therapy
1990
The secret ally: immunostimulation by anticancer drugs
2012
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer.
1989
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Lymphatic Mapping and Sentinel Node Biopsy in the Patient With Breast Cancer
1996 Standout
Hepatocellular Carcinoma
2019 Standout
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
2015 Standout
Inferring tumour purity and stromal and immune cell admixture from expression data
2013 Standout
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13
2005
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Clinical decision-making in early breast cancer.
1993
Breast Cancer Treatment
2019 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
1992 Standout
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Interobserver Agreement Among Pathologists for Semiquantitative Hormone Receptor Scoring in Breast Carcinoma
2012
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
2009
Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor–Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23
2001
Metabolic reprogramming and cancer progression
2020 StandoutScience
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Gene expression profiles of human breast cancer progression
2003
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work
1997
The incidence of secondary leukemias.
1999
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Works of Robert P. Gray being referenced
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
2009
Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer
2009
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
2013
Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer
2003
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
1995
Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry
2001
Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
1989
Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
2008
HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197
2008